Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

References

• Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6–38.
   PubMed Web of Science ®Google Scholar
• Hu XH, Raskin NH, Cowan R, et al. Treatment of migraine with rizatriptan: when to take the medication. Headache. 2002;42(1):16–20.
   PubMed Web of Science ®Google Scholar
• Cady R, Elkind A, Goldstein J, et al. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20(9):1465–1472.
   PubMed Web of Science ®Google Scholar
• Moschiano F, D’Amico D, Allais G, et al. Early triptan intervention in migraine: an overview. Neurol Sci. 2005;26(S2):s108–s110.
   PubMedGoogle Scholar
• Brandes JL, Kudrow D, Cady R, et al. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25(9):735–742.
   PubMed Web of Science ®Google Scholar
• Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006;46(6):914–924.
   PubMed Web of Science ®Google Scholar
• Ng-Mak DS, Hu XH, Chen Y, et al. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. Int J Clin Pract. 2007;61(7):1091–1111.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G, et al. Early versus non-early intervention in acute migraine-‘Act when Mild (AwM)’: a double-blind, placebocontrolled trial of almotriptan. Cephalalgia. 2008;28(4):383–391.
   PubMed Web of Science ®Google Scholar
• Mannix L. A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future. Expert Opin Pharmacother. 2008;9(6):1001–1011.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick D, Goadsby P, et al. Ubrogepant is effective in the acute treatment of migraine with mild pain. Neurology. 2020;94(15 Suppl):4726.
   Google Scholar
• Lipton RB, Munjal S, Buse DC, et al. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2016;56(10):1635–1648.
   PubMed Web of Science ®Google Scholar
• Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action – review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222–e2232.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904.
   PubMed Web of Science ®Google Scholar
• Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90.
   PubMed Web of Science ®Google Scholar
• Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain. 2019;20(1):84.
   PubMedGoogle Scholar
• Lipton RB, Lombard L, Ruff DD, et al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. J Headache Pain. 2020;21(1):20.
   PubMed Web of Science ®Google Scholar
• Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343–1357.
   PubMed Web of Science ®Google Scholar
• The international classification of headache disorders: 2nd edition. Cephalalgia. 2004;24:9–160.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Migraine: developing drugs for acute treatment guidance for industry. 2018. [cited 2020 Nov 19]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM419465.pdf.
   Google Scholar
• Goadsby PJ. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008;28(2_suppl):36–41.
   PubMedGoogle Scholar
• Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the spectrum study. Headache. 2000;40(10):792–797.
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther. 2000;22(9):1035–1048.
   PubMed Web of Science ®Google Scholar
• Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache. 2002;42(1):28–31.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache. 2004;44(7):669–673.
   PubMed Web of Science ®Google Scholar
• Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005;45(5):538–545.
   PubMed Web of Science ®Google Scholar
• Pascual J. Clinical benefits of early triptan therapy for migraine. Headache. 2002;42(Suppl 1):10–17.
   PubMedGoogle Scholar